Home › Companies › Vir Biotechnology, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Vir Biotechnology, Inc.’s Form 8-K, filed May 28, 2026 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of May 26, 2026: 5 items on Vir Biotechnology, Inc.’s Form 8-K, filed May 28, 2026: 3 elected · 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Vir Biotechnology, Inc. in the interactive database Compare manager voting policies
These tallies are Vir Biotechnology, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 28, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Robert More, MBA | 114,856,835 | -- | -- | 6,833,096 | 16,677,343 | 94% | Elected | — |
| Elect Director: Janet Napolitano, J.D. | 67,235,175 | -- | -- | 54,454,756 | 16,677,343 | 55% | Elected | — |
| Elect Director: Elliott Sigal, M.D., Ph.D. | 115,030,681 | -- | -- | 6,659,250 | 16,677,343 | 95% | Elected | — |
| 2. Advisory Vote on Executive Compensation | 108,453,963 | 11,863,405 | 1,372,563 | -- | 16,677,343 | 90% | Approved | — |
| 3. Ratification of Appointment of Independent Registered Public Accounting Firm | 137,048,756 | 153,836 | 1,164,682 | -- | 0 | 99.8% | Approved | — |
This meeting is also recorded here as May 25, 2026; both records come from the same filing, so the date should be checked against it.
Source: Vir Biotechnology, Inc., Form 8-K, filed with the SEC on May 28, 2026 — read the filing on EDGAR.
Each item below shows how the 261 asset managers that disclosed a Vir Biotechnology, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Elliott Sigal, M.D., Ph.D.
Vir Biotechnology, Inc.’s own tally for this item (“Elect Director: Elliott Sigal, M.D., Ph.D.”): 115,030,681 for, 6,659,250 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 40,481,497 for, 1,494,866 withheld, 45 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,741,932 | 0 | 45 | 29,465 | For |
| BlackRock | 12,319,267 | 0 | 0 | 0 | For |
| State Street | 4,718,394 | 0 | 0 | 6,440 | For |
| Fidelity | 2,343,079 | 0 | 0 | 580,873 | Mixed |
| Charles Schwab | 1,027,760 | 0 | 0 | 0 | For |
| TIAA | 991,280 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 730,367 | Withhold |
| JPMorgan | 581,078 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,342 | 0 | 0 | 0 | For |
| American Century | 295,666 | 0 | 0 | 0 | For |
| Nationwide | 264,005 | 0 | 0 | 0 | For |
| Jackson National | 191,873 | 0 | 0 | 27,183 | Mixed |
| Invesco | 208,575 | 0 | 0 | 0 | For |
| Equitable | 130,368 | 0 | 0 | 64,830 | Mixed |
| GuideStone | 155,800 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,552 | 0 | 0 | 0 | For |
| Thrivent | 112,215 | 0 | 0 | 0 | For |
| Prudential/PGIM | 99,017 | 0 | 0 | 12,130 | Mixed |
| BNY Mellon | 96,522 | 0 | 0 | 0 | For |
| Principal | 93,527 | 0 | 0 | 0 | For |
| Global X | 86,721 | 0 | 0 | 0 | For |
| ProShares | 85,671 | 0 | 0 | 0 | For |
| Empower | 84,405 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,781 | 0 | 0 | 5,566 | Mixed |
Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.
Combines 4 wordings of this item as funds reported it.
55% Majority: yes · of votes cast
Description as filed by funds: To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Janet Napolitano, J.D.
Vir Biotechnology, Inc.’s own tally for this item (“Elect Director: Janet Napolitano, J.D.”): 67,235,175 for, 54,454,756 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 55% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 14,439,500 for, 27,536,664 withheld, 243 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 9,431,553 | 0 | 243 | 5,339,646 | Mixed |
| BlackRock | 0 | 0 | 0 | 12,319,267 | Withhold |
| State Street | 4,711,075 | 0 | 0 | 13,759 | For |
| Fidelity | 0 | 0 | 0 | 2,923,952 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 1,027,760 | Withhold |
| TIAA | 0 | 0 | 0 | 991,280 | Withhold |
| Dimensional | 0 | 0 | 0 | 730,367 | Withhold |
| JPMorgan | 0 | 0 | 0 | 581,078 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 500,000 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 364,342 | Withhold |
| American Century | 0 | 0 | 0 | 295,666 | Withhold |
| Nationwide | 0 | 0 | 0 | 264,005 | Withhold |
| Jackson National | 0 | 0 | 0 | 219,056 | Withhold |
| Invesco | 208,575 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 195,198 | Withhold |
| GuideStone | 0 | 0 | 0 | 155,800 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 148,552 | Withhold |
| Thrivent | 0 | 0 | 0 | 112,215 | Withhold |
| Prudential/PGIM | 0 | 0 | 0 | 111,147 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 96,522 | Withhold |
| Principal | 0 | 0 | 0 | 93,527 | Withhold |
| Global X | 0 | 0 | 0 | 86,721 | Withhold |
| ProShares | 0 | 0 | 0 | 85,671 | Withhold |
| Empower | 0 | 0 | 0 | 84,405 | Withhold |
| Lincoln Financial | 61,000 | 0 | 0 | 21,347 | Mixed |
Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.
Combines 4 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
Description as filed by funds: To elect the following three nominees for director to hold office until the 2029 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Robert More, MBA
Vir Biotechnology, Inc.’s own tally for this item (“Elect Director: Robert More, MBA”): 114,856,835 for, 6,833,096 withheld, per its Form 8-K filed May 28, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 40,481,496 for, 1,494,866 withheld, 46 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,741,931 | 0 | 46 | 29,465 | For |
| BlackRock | 12,319,267 | 0 | 0 | 0 | For |
| State Street | 4,718,394 | 0 | 0 | 6,440 | For |
| Fidelity | 2,343,079 | 0 | 0 | 580,873 | Mixed |
| Charles Schwab | 1,027,760 | 0 | 0 | 0 | For |
| TIAA | 991,280 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 730,367 | Withhold |
| JPMorgan | 581,078 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,342 | 0 | 0 | 0 | For |
| American Century | 295,666 | 0 | 0 | 0 | For |
| Nationwide | 264,005 | 0 | 0 | 0 | For |
| Jackson National | 191,873 | 0 | 0 | 27,183 | Mixed |
| Invesco | 208,575 | 0 | 0 | 0 | For |
| Equitable | 130,368 | 0 | 0 | 64,830 | Mixed |
| GuideStone | 155,800 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,552 | 0 | 0 | 0 | For |
| Thrivent | 112,215 | 0 | 0 | 0 | For |
| Prudential/PGIM | 99,017 | 0 | 0 | 12,130 | Mixed |
| BNY Mellon | 96,522 | 0 | 0 | 0 | For |
| Principal | 93,527 | 0 | 0 | 0 | For |
| Global X | 86,721 | 0 | 0 | 0 | For |
| ProShares | 85,671 | 0 | 0 | 0 | For |
| Empower | 84,405 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,781 | 0 | 0 | 5,566 | Mixed |
Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.
Combines 7 wordings of this item as funds reported it.
90% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.
Vir Biotechnology, Inc.’s own tally for this item (“2. Advisory Vote on Executive Compensation”): 108,453,963 for, 11,863,405 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,755,300 | 16,136 | 8 | 0 | For |
| BlackRock | 12,319,267 | 0 | 0 | 0 | For |
| State Street | 4,722,574 | 2,260 | 0 | 0 | For |
| Fidelity | 2,343,079 | 580,873 | 0 | 0 | Mixed |
| Charles Schwab | 1,027,760 | 0 | 0 | 0 | For |
| TIAA | 991,280 | 0 | 0 | 0 | For |
| Dimensional | 0 | 730,367 | 0 | 0 | Against |
| JPMorgan | 0 | 581,078 | 0 | 0 | Against |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,342 | 0 | 0 | 0 | For |
| American Century | 0 | 295,666 | 0 | 0 | Against |
| Nationwide | 261,209 | 2,796 | 0 | 0 | For |
| Jackson National | 191,873 | 27,183 | 0 | 0 | Mixed |
| Invesco | 208,575 | 0 | 0 | 0 | For |
| Equitable | 195,198 | 0 | 0 | 0 | For |
| GuideStone | 155,800 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,552 | 0 | 0 | 0 | For |
| Thrivent | 112,215 | 0 | 0 | 0 | For |
| Prudential/PGIM | 0 | 111,147 | 0 | 0 | Against |
| BNY Mellon | 96,522 | 0 | 0 | 0 | For |
| Principal | 93,527 | 0 | 0 | 0 | For |
| Global X | 0 | 86,721 | 0 | 0 | Against |
| ProShares | 85,671 | 0 | 0 | 0 | For |
| Empower | 84,405 | 0 | 0 | 0 | For |
| Lincoln Financial | 61,000 | 21,347 | 0 | 0 | Mixed |
Fund voting reports, all 66 managers: 39,433,128 for, 2,543,040 against, 7,828 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| ARCH Venture Management, LLC | 12,916,663 | 0 | 0 | 0 | For |
| SB INVESTMENT ADVISERS (UK) LTD | 10,948,093 | 0 | 0 | 0 | For |
| State Street | 6,738,016 | 30,422 | 0 | 0 | For |
| BlackRock | 4,962,629 | 33,031 | 0 | 0 | For |
| Ballentine Partners, LLC | 2,666,173 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,487,950 | 0 | 0 | 0 | For |
| Fidelity | 0 | 2,020,999 | 0 | 0 | Against |
| Soleus Capital Management, L.P. | 2,002,000 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,325,110 | 0 | 0 | 0 | For |
| Charles Schwab | 1,170,967 | 0 | 0 | 0 | For |
| Candriam S.C.A. | 0 | 1,135,763 | 0 | 0 | Against |
| Point72 | 1,114,706 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 1,070,812 | 0 | 0 | 0 | For |
| Nuveen | 1,018,998 | 0 | 0 | 0 | For |
| Vanguard | 899,759 | 0 | 0 | 0 | For |
| Northern Trust | 855,424 | 14,399 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 755,223 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 722,654 | 0 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 650,989 | 0 | 0 | 0 | For |
| Avidity Partners Management LP | 0 | 650,000 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 603,920 | 0 | 0 | 0 | For |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 580,755 | 0 | 0 | Against |
| Citadel | 566,781 | 0 | 0 | 0 | For |
| PRINCIPAL GLOBAL INVESTORS | 547,753 | 0 | 0 | 0 | For |
| DE Shaw | 532,157 | 0 | 0 | 0 | For |
Institutional-manager reports, all 216 managers: 60,949,212 for, 7,764,605 against, 125,115 abstained. Showing the 25 largest; see all in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.8% Approved · of votes cast
Description as filed by funds: TO RATIFY THE APPOINTMENT BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Vir Biotechnology, Inc.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Public Accounting Firm”): 137,048,756 for, 153,836 against — passed, per its Form 8-K filed May 28, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 66 asset managers below reported 41,968,356 for, 223 against, 7,828 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 14,771,434 | 0 | 8 | 0 | For |
| BlackRock | 12,319,267 | 0 | 0 | 0 | For |
| State Street | 4,724,611 | 223 | 0 | 0 | For |
| Fidelity | 2,923,952 | 0 | 0 | 0 | For |
| Charles Schwab | 1,027,760 | 0 | 0 | 0 | For |
| TIAA | 991,280 | 0 | 0 | 0 | For |
| Dimensional | 730,367 | 0 | 0 | 0 | For |
| JPMorgan | 581,078 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 500,000 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 364,342 | 0 | 0 | 0 | For |
| American Century | 295,666 | 0 | 0 | 0 | For |
| Nationwide | 264,005 | 0 | 0 | 0 | For |
| Jackson National | 219,056 | 0 | 0 | 0 | For |
| Invesco | 208,575 | 0 | 0 | 0 | For |
| Equitable | 195,198 | 0 | 0 | 0 | For |
| GuideStone | 155,800 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,552 | 0 | 0 | 0 | For |
| Thrivent | 112,215 | 0 | 0 | 0 | For |
| Prudential/PGIM | 111,147 | 0 | 0 | 0 | For |
| BNY Mellon | 96,522 | 0 | 0 | 0 | For |
| Principal | 93,527 | 0 | 0 | 0 | For |
| Global X | 86,721 | 0 | 0 | 0 | For |
| ProShares | 85,671 | 0 | 0 | 0 | For |
| Empower | 84,405 | 0 | 0 | 0 | For |
| Lincoln Financial | 82,347 | 0 | 0 | 0 | For |
Showing the 25 largest of 66 asset managers. See all 66 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 168,651,974 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 8.76% |
| 2 | BlackRock | 7.30% |
| 3 | State Street | 2.80% |
| 4 | Fidelity | 1.73% |
| 5 | Charles Schwab | 0.61% |
| 6 | TIAA | 0.59% |
| 7 | Dimensional | 0.43% |
| 8 | JPMorgan | 0.34% |
| 9 | Delaware/Macquarie | 0.30% |
| 10 | Columbia Threadneedle | 0.22% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | ARCH Venture Management, LLC | 7.66% |
| 2 | SB INVESTMENT ADVISERS (UK) LTD | 6.49% |
| 3 | State Street | 4.01% |
| 4 | BlackRock | 2.96% |
| 5 | Ballentine Partners, LLC | 1.58% |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1.48% |
| 7 | Fidelity | 1.20% |
| 8 | Soleus Capital Management, L.P. | 1.19% |
| 9 | PICTET ASSET MANAGEMENT SA | 0.79% |
| 10 | Charles Schwab | 0.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 10.67% | 13F |
| SVF Endurance (Cayman) Ltd. | 7.78% | DEF14A |
| Entities affiliated with ARCH Venture Partners, L.P. | 7.66% | DEF14A |
| Vanguard Group | 7.44% | 13F |
| SB Investment Advisers (UK) Limited | 6.49% | 13G |
| Glaxo Group Limited | 5.07% | DEF14A |
| State Street | 4.23% | 13F |
| Goldman Sachs | 1.93% | 13F |
| Morgan Stanley | 1.59% | 13F |
| Geode Capital | 1.58% | 13F |
Percentages above are of 168,651,974 shares outstanding, as reported by Vir Biotechnology, Inc. on its Form 10-Q dated April 29, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vir Biotechnology, Inc.’s 10-Q dated April 29, 2026. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At Vir Biotechnology, Inc.'s shareholder meeting held May 26, 2026, in the 2025-2026 proxy season, 261 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,641 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — Vir Biotechnology, Inc.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Vir Biotechnology, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 28, 2026.
Vir Biotechnology, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.